Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Fimasartan and Rosuvastatin
Yung NA
Essential Hypertension, Dyslipidemia
1 trial -
dabigatran
Yung NA
Atrial Fibrillation
1 trial -
Prednisone + Jakavi(ruxolitinib)
Yung NA
GVHD - Graft-Versus-Host Disease
1 trial -
gemcitabine
Yung NA
Muscle Invasive Bladder Urothelial Carcinoma
1 trial -
BRI-1501
Yung NA
Gastric Ulcer
1 trial -
Fimasartan
Yung NA
Hypertension
1 trial -
Fimasartan
Yung NA
Essential Hypertension
1 trial -
Fimasartan/Atorvastatin Combination Tablet
Yung NA
Hypertension
1 trial -
Rabeprazole Sodium 10mg
Yung NA
Gastroesophageal Reflux Disease
1 trial -
Pregabalin
Yung NA
Diabetic Peripheral Neuropathy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources